Published in Arterioscler Thromb Vasc Biol on May 01, 2000
Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol (2008) 1.86
Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol (2005) 1.37
Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol (2007) 1.34
Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed) (2012) 1.28
Endothelium and its alterations in cardiovascular diseases: life style intervention. Biomed Res Int (2014) 1.03
Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb Res (2010) 0.98
Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis (2009) 0.84
Porphyromonas gingivalis infection and prothrombotic effects in human aortic smooth muscle cells. Thromb Res (2008) 0.83
Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor. Thromb Res (2009) 0.81
Plasmin-dependent proteolysis of tissue factor pathway inhibitor in a mouse model of endotoxemia. J Thromb Haemost (2013) 0.79
Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation. J Physiol (2016) 0.79
The Jeremiah Metzger Lecture. Hypercoagulable states: challenges and opportunities. Trans Am Clin Climatol Assoc (2001) 0.78
Circulating thrombotic and haemostatic components in patients with coronary artery disease. Indian J Clin Biochem (2010) 0.78
Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure. Front Biosci (Elite Ed) (2012) 0.77
Peroxisome Proliferator-Activated Receptor γ Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages. PPAR Res (2016) 0.75
Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside. Biologics (2008) 0.75
Cyclic strain delays the expression of tissue factor induced by thrombin in human umbilical vein endothelial cells. Int J Angiol (2011) 0.75
The detection of venous thrombosis of the legs using 125-I-labelled fibrinogen. Br J Surg (1968) 10.22
Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell (1999) 7.33
Natural history of postoperative deep-vein thrombosis. Lancet (1969) 5.18
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
125-I-labelled fibrinogen test adapted for routine screening for deep-vein thrombosis. Lancet (1970) 4.48
Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med (1999) 4.33
Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet (1997) 3.40
Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation (1997) 3.33
Oral contraceptives, antithrombin- III activity, and postoperative deep-vein thrombosis. Lancet (1976) 2.77
Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost (2005) 2.70
Deep vein thrombosis of the leg. Is there a "high risk" group? Am J Surg (1970) 2.66
Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med (2001) 2.66
Low doses of heparin in prevention of deep-vein thrombosis. Lancet (1971) 2.38
Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med (2001) 2.31
Downregulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation (1998) 2.26
Spatiotemporal relation between gap junctions and fascia adherens junctions during postnatal development of human ventricular myocardium. Circulation (1994) 2.21
Efficacy of low doses of heparin in prevention of deep-vein thrombosis after major surgery. A double-blind, randomised trial. Lancet (1972) 2.20
Altered connexin expression in human congestive heart failure. J Mol Cell Cardiol (2001) 2.15
Postoperative deep-vein thrombosis. Effect of intensive prophylaxis. Lancet (1969) 2.09
Effects of an Igf1 gene null mutation on mouse reproduction. Mol Endocrinol (1996) 2.08
Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol (2001) 2.06
A physiological study of elastic compression stockings in venous disorders of the leg. Br J Surg (1980) 2.06
Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation (1993) 2.05
Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem (1989) 2.05
The origin of deep vein thrombosis: a venographic study. Br J Radiol (1971) 1.96
Altered patterns of gap junction distribution in ischemic heart disease. An immunohistochemical study of human myocardium using laser scanning confocal microscopy. Am J Pathol (1991) 1.93
Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation (1997) 1.91
Treatment of deep vein thrombosis. A trial of heparin, streptokinase, and arvin. Br Med J (1969) 1.82
Late results of treatment of deep vein thrombosis. Br Med J (1969) 1.77
Gap junctions and connexin expression in human suburothelial interstitial cells. BJU Int (2002) 1.75
The spatial distribution and relative abundance of gap-junctional connexin40 and connexin43 correlate to functional properties of components of the cardiac atrioventricular conduction system. J Cell Sci (1993) 1.65
The origin of thrombi in the deep veins of the lower limb: a venographic study. Br J Surg (1978) 1.65
Loss of desmoplakin isoform I causes early onset cardiomyopathy and heart failure in a Naxos-like syndrome. J Med Genet (2006) 1.64
Sugar intake, serum insulin and platelet adhesiveness in men with and without peripheral vascular disease. Postgrad Med J (1969) 1.63
Dissociated spatial patterning of gap junctions and cell adhesion junctions during postnatal differentiation of ventricular myocardium. Circ Res (1997) 1.63
Cold adaptation and the seasonal distribution of acute myocardial infarction. QJM (1999) 1.62
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Nuclear pore absence from areas of close association between nucleus and vacuole in synchronous yeast cultures. J Ultrastruct Res (1976) 1.55
Hyperexcitability of convergent colon and bladder dorsal root ganglion neurons after colonic inflammation: mechanism for pelvic organ cross-talk. Neurogastroenterol Motil (2006) 1.51
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol (1998) 1.48
Antithrombin-TRI (Ala382 to Thr) causing severe thromboembolic tendency undergoes the S-to-R transition and is associated with a plasma-inactive high-molecular-weight complex of aggregated antithrombin. Br J Haematol (1995) 1.47
Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol (1986) 1.45
Late-onset homozygous protein C deficiency. Lancet (1991) 1.43
Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy. Heart (1996) 1.41
Lipid peroxides and atherosclerosis. BMJ (1989) 1.41
Rings of membrane sterols surround the openings of vesicles and fenestrae, in capillary endothelium. J Cell Biol (1983) 1.40
The effect of low molecular weight heparin on intimal hyperplasia in vein grafts. Eur J Vasc Surg (1994) 1.39
Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet (1994) 1.39
Low serum cholesterol and suicide. Lancet (1992) 1.39
Influence of whole blood on standard curve for heparin measurement--possible heparin binding by red cells. Thromb Haemost (1989) 1.39
Lung function test findings in patients with chronic fatigue syndrome (CFS) Aust N Z J Med (1996) 1.39
Fibrinolytic activity and postoperative deep-vein thrombosis. Lancet (1974) 1.39
Inflammation, innate immunity and blood coagulation. Hamostaseologie (2010) 1.39
An objective study of alternative methods of heparin administration. Thromb Res (1980) 1.38
Efficacy of low-dose heparin in prevention of extensive deep-vein thrombosis in patients undergoing total-hip replacement. Lancet (1976) 1.38
Review of present status of prophylaxis of venous thromboembolism. Proc R Soc Med (1974) 1.37
Distinct patterns of dystrophin organization in myocyte sarcolemma and transverse tubules of normal and diseased human myocardium. Circulation (2000) 1.37
Connexin45 expression is preferentially associated with the ventricular conduction system in mouse and rat heart. Circ Res (1998) 1.34
Myocardial infarction and deep-vein thrombosis. Br Med J (1971) 1.33
Acquired dysfibrinogenaemia in acute and chronic liver disease. Br J Haematol (1977) 1.30
Plasma exchange and platelet function in Raynaud's phenomenon. Thromb Res (1981) 1.28
Endotoxaemia and renal failure in cirrhosis and obstructive jaundice. Br Med J (1976) 1.25
In vivo detection of c-Met expression in a rat C6 glioma model. J Cell Mol Med (2007) 1.25
Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by interleukin 5: the role of specific adhesion molecules and phosphatidylinositol 3-kinase. J Exp Med (1998) 1.25
The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation (2001) 1.24
Innate immunity and coagulation. J Thromb Haemost (2011) 1.24
The changing pattern of venous thromboembolic disease. Haemostasis (1997) 1.23
Nuclear pore formation and the cell cycle in Saccharomyces cerevisiae. Exp Cell Res (1977) 1.21
Detection of microdomains in biomembranes. An appraisal of recent developments in freeze-fracture cytochemistry. Biochim Biophys Acta (1983) 1.21
Chamber-related differences in connexin expression in the human heart. J Mol Cell Cardiol (1999) 1.19
Gap junction remodeling in hypertrophied left ventricles of aortic-banded rats: prevention by angiotensin II type 1 receptor blockade. J Mol Cell Cardiol (2001) 1.19
Graduated, static, external compression of the lower limb: a physiological assessment. Br J Surg (1980) 1.18
Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients. J Bone Joint Surg Br (1989) 1.18
Connexin45 (alpha 6) expression delineates an extended conduction system in the embryonic and mature rodent heart. Dev Genet (1999) 1.18
Deep-vein thrombosis in patients with fractures of the femoral neck. Br J Surg (1972) 1.18
Remodeling of gap junctional coupling in hypertrophied right ventricles of rats with monocrotaline-induced pulmonary hypertension. Circ Res (2000) 1.18
Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res (2000) 1.18
beta-thromboglobulin and platelet factor 4 levels in retinal vein occlusion. Br J Ophthalmol (1983) 1.16
Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. Br Med J (Clin Res Ed) (1982) 1.16
Individual gap junction plaques contain multiple connexins in arterial endothelium. Circ Res (1999) 1.14
Connexin45, a major connexin of the rabbit sinoatrial node, is co-expressed with connexin43 in a restricted zone at the nodal-crista terminalis border. J Histochem Cytochem (1999) 1.12
Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Hum Mutat (1995) 1.12
Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol (1997) 1.11
The problems of thrombosis in the deep veins of the leg. Ann R Coll Surg Engl (1969) 1.11
Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol (1995) 1.11
Detection of deep vein thrombosis: survey and current status. Prog Cardiovasc Dis (1975) 1.11
Treatment of deep-vein thrombosis with streptokinase. Br J Surg (1969) 1.10
Femoral vein thrombosis and total hip replacement. Br Med J (1977) 1.10
An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol (1997) 1.10
Gap junction distribution in adult mammalian myocardium revealed by an anti-peptide antibody and laser scanning confocal microscopy. J Cell Sci (1991) 1.09
Plasma heparin levels after administration of calcium and sodium salts of heparin. Thromb Res (1976) 1.09
The I 125 -labeled fibrinogen test and phlebography in the diagnosis of deep vein thrombosis. Milbank Mem Fund Q (1972) 1.09
Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol (1995) 1.09
Deep vein thrombosis. Detection and prevention. Circulation (1975) 1.08
Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res (2000) 1.08
The current status of low-dose heparin in the prophylaxis of thrombophlebitis and pulmonary embolism. World J Surg (1978) 1.08